/
J Investig Allergol Clin Immunol 2006; Vol. 16(4): 268-270 J Investig Allergol Clin Immunol 2006; Vol. 16(4): 268-270

J Investig Allergol Clin Immunol 2006; Vol. 16(4): 268-270 - PDF document

celsa-spraggs
celsa-spraggs . @celsa-spraggs
Follow
414 views
Uploaded On 2015-08-10

J Investig Allergol Clin Immunol 2006; Vol. 16(4): 268-270 - PPT Presentation

ID: 104327

Share:

Link:

Embed:

Download Presentation from below link

Download Pdf The PPT/PDF document "J Investig Allergol Clin Immunol 2006; V..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

J Investig Allergol Clin Immunol 2006; Vol. 16(4): 268-270 © 2006 Esmon PublicidadO Sener et al269 Figure 1. Pustular erythematous eruption on the third day Figure 2. Inflammatory cell infiltration especially inand rubellaÐrubeola serology. All medications werestopped and cold compresses were applied for the fever.A complete blood count revealed hemoglobin 11.8 g,sedimentation rate 20 mm in the first hour. Her liverphosphatase 118 U/L, serum albumin 3.2 g/dL, andprothrombin time 12 seconds. Viral hepatitis serology(IgM antibody to hepatitis A antigen, hepatitis B surfaceantigen, and hepatitis C antibody) were negative.normal limits. RubellaÐrubeola serology revealed highso these viral infections were ruled out. A mononucleosisantinuclear, anti-double-stranded DNA, anti-smooth-muscle, and anti-liver-kidney-microsome antibodies werenegative. Abdominal ultrasound showed uniform liverenlargement with a slight increase in echo texture, andinfiltration especially in perivascular, interstitial andmelanophages were observed in the dermis. The epidermislayer. Morphologic findings were consistent with awith clinical history.A diagnosis of DHS was thus based on the patientÕsmedical history, clinical findings and laboratory testquickly, and laboratory test results returned to normallevels within 2 weeks. We planned to taper off herwas discharged. After 8 weeks, her follow-up examinationDiscussiondecades later. Dapsone has been used as a first-linetreatment for leprosy since the 1950s [2]. It is also the J Investig Allergol Clin Immunol 2006; Vol. 16(4): 268-270 herpetiformis. Although good results may be obtained forsome patients with a gluten-free diet, the difficulty ofmany. Itching and blister formation can be controlled with. Itching and blister formation can be controlled withDapsone is absorbed well from the gut and primarilymetabolized through N-acetylation and N-hydroxylation(oxidation) [3]. The hydroxylamine metabolite and otherbeen thought to cause the hematologic adverse effectsand hemolytic anemia [3]. It is excreted by the kidney, buthas significant enterohepatic circulation [4]. Thus, a longemerge after a long metabolite impact period [4].fever, rash, lymphadenopathy and different degrees oforgan involvement. This entity is also termed drugThis entity is also termed drugmanifestation of DRESS syndrome. Typically thetherapy. Patients present with fever, malaise, a generalizedcutaneous eruption, lymphadenopathy, hemolytic anemia,and hepatitis. The rash, which is often initially a benignThe rash, which is often initially a benignhepatocellular and cholestatic pattern [6] although drug-induced cholangitis has been reported in a patient withDHS [8]. According to Richardus and Smith [9], a truesimultaneously, and c) symptoms unrelated to leprosy orimportant in the pathogenesis of DHS. A reduction in N-decreased total clearance of dapsone [6]. Aging orpreexisting liver disease may offer relative protectionagainst adverse effects because of decreased enzymemetabolites [6]. The long elimination half-life thatThe long elimination half-life thatStrong protein binding of the drug itself (70%-90%) andits major metabolite, monacetyl dapsone (99%),contribute to that long half-life [4]. Systemiccorticosteroids have been used to treat DHS; however,no comparative studies regarding their effectiveness havedays in organs through protein binding and enterohepaticrecirculation, slow tapering off the corticosteroid therapyover at least 1 month with close monitoring of organhowever, deaths have been reported [10]. Physicians,in the fields of dermatology and allergy, should be awareReferences 1.Leonard JN, Fry L. Treatment and management of dermatitis 2.Lowe J. Treatment of leprosy by diamine diphenyl sulfone 3.Sago J, Hall III RP. Dapsone. Dermatol Ther. 2002;15:340- 4.Zuidema J, Hilbers-Modderman ESM, Merkus FWHM.1986;11:299-315. 5.Gruchalla RS. Drug allergy. J Allergy Clin Immunol.2003;111(2):S548-59. 6.Prussick R, Shear NH. Dapsone hypersensitivity syndrome.J Am Acad Dermatol. 1996;35:346-9. 7.Leslie KS, Gaffney K, Ross CN, Ridley S, Barker TH,Garioch JJ. A near fatal case of the dapsone hypersensitivity 8.Itha S, Kumar A, Dhingra S, Choudhuri G. Dapsone induced 9.Richardus JH, Smith TC. Increased incidence in leprosy ofmultidrug therapy. Lepr Rev. 1989;60:267-73.10.Lau G. A fatal case of drug-induced multi-organ damage ina patient with HansenÕs disease: dapsone syndrome or Gulhane Military Medical AcademyDivision of Allergy06018 Etlik, Ankara, Turkey J Investig Allergol Clin Immunol 2006; Vol. 16(4): 268-270Severe Dapsone HypersensitivitySyndromeO Sener, A PahsaDivision of Allergy, Department of Microbiology and Clinical Microbiology, Department of Pathology,Gulhane Military Medical Academy, Ankara, Turkey leprosy and a variety of blistering skin diseases. It may cause a severe adverse drug reaction with multiorganinvolvement known as dapsone hypersensitivity syndrome. We report the case of a 21-year-old female patientwith dapsone hypersensitivity syndrome. The clinical presentation mimicked a viral exanthema. Dapsone hypersensitivity. Dermatitis herpetiformis. con afectaci—n multiorg‡nica denominada s’ndrome de hipersensibilidad a la dapsona. Presentamos el caso de unaIntroductionused as a first line drug for leprosy. In Europe and theUnited States of America, however, it finds applicationdermatitis herpetiformis [1]. The most frequent sideeffects are dose-related methemoglobinemia andhemolytic anemia, and rarely, it can cause an idiosyncratic(DHS). We report the case of a woman with DHSA 21-year-old white Turkish woman was referred toearlier. She was given a diagnosis of dermatitisherpetiformis based on a skin biopsy, and she was givenwithin a week of starting therapy. Dapsone-inducedstopped. Four weeks later, she consulted her primary carephysician with complaints of high fever, malaise,lymphadenopathy, maculopapular skin rash, and painfulHg, and heart rate was 112tender were noted. She had a 4-cm slightly tender enlargedliver below the costal margin. There was no splenomegalyStevensÐJohnson-like lesions in the oral cavity. Lung and